Al's Comment:

This is an exciting partnership between xCures and DDRFA, which brings together their respective strengths. xCures possesses the capabilities to collect, structure, and analyze patient data, while DDRFA, in collaboration with over 60 brain tumor foundations, including the Musella Foundation, has extensive access to patients with DMG and DIPG.

 

The crucial element driving progress in this endeavor is data. The registry established through this partnership will enable researchers to examine the utilization of various treatments, both in isolation and in combination, assess their efficacy, and study the natural progression of these diseases. This comprehensive data repository also offers the possibility of creating artificial control groups, potentially eliminating the necessity for placebo use in clinical trials for these conditions. Additionally, the platform facilitates the seamless implementation of prospective virtual trials on treatment combinations.

 

As a consultant to xCures, as well as a DDRFA partner,  I am thrilled to be a part of this groundbreaking initiative. If you are interested in participating, please follow the link provided in the article. While focused on diffuse midline glioma, which includes DIPG, the Musella Foundation and Cancer Commons are leveraging this platform for all malignant brain tumors, as well as other cancer types.

xCures and DDRFA partner to make an impact on patient-driven DIPG & DMG research